Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from abacavir/lamivudine plus a third antiretroviral to E/C/F/TAF in virologically suppressed adults with HIV-1
2015-002711-15Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, abacavir and 1 more in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA <50 copies/mL at Week 24. Started Sep 2015; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamideabacavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-002711-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002711-15.